Evidence map›Paper›PMID 39292373›Full record

ArticlePharmacological reports : PR2025

JG26 attenuates ADAM17 metalloproteinase-mediated ACE2 receptor processing and SARS-CoV-2 infection in vitro.

Valentina Gentili, Silvia Beltrami, Doretta Cuffaro, Giorgia Cianci, Gloria Maini, Roberta Rizzo, Marco Macchia, Armando Rossello, Daria Bortolotti, Elisa Nuti

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacological reports : PR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Valentina Gentili *Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Via Luigi Borsari 46, Ferrara, 44121, Italy.
Silvia Beltrami *Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Via Luigi Borsari 46, Ferrara, 44121, Italy.
Doretta CuffaroDepartment of Pharmacy, University of Pisa, Via Bonanno 6, Pisa, 56126, Italy.ORCID http://orcid.org/0000-0002-8842-542X
Giorgia CianciDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Via Luigi Borsari 46, Ferrara, 44121, Italy.
Gloria MainiDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Via Luigi Borsari 46, Ferrara, 44121, Italy.
Roberta RizzoDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Via Luigi Borsari 46, Ferrara, 44121, Italy.
Marco MacchiaDepartment of Pharmacy, University of Pisa, Via Bonanno 6, Pisa, 56126, Italy.
Armando RosselloDepartment of Pharmacy, University of Pisa, Via Bonanno 6, Pisa, 56126, Italy.ORCID http://orcid.org/0000-0002-6795-8091
Daria Bortolotti *Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Via Luigi Borsari 46, Ferrara, 44121, Italy. brtdra@unife.it.
Elisa Nuti *Department of Pharmacy, University of Pisa, Via Bonanno 6, Pisa, 56126, Italy. elisa.nuti@unipi.it.ORCID http://orcid.org/0000-0003-2669-5376

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundADAM17 is a metalloprotease implicated in the proteolysis of angiotensin-converting enzyme 2 (ACE2), known to play a critical role in the entry and spread of SARS-CoV-2. In this context, ADAM17 results as a potential novel target for controlling SARS-CoV-2 infection.

methodsIn this study, we investigated the impact on ACE2 surface expression and the antiviral efficacy against SARS-CoV-2 infection of the selective ADAM17 inhibitor JG26 and its dimeric (compound 1) and glycoconjugate (compound 2) derivatives using Calu-3 human lung cells.

resultsNone of the compounds exhibited cytotoxic effects on Calu-3 cells up to a concentration of 25 µM. Treatment with JG26 resulted in partial inhibition of both ACE2 receptor shedding and SARS-CoV-2 infection, followed by compound 1.

conclusionJG26, an ADAM17 inhibitor, demonstrated promising antiviral activity against SARS-CoV-2 infection, likely attributed to reduced sACE2 availability, thus limiting viral dissemination.

Indexed as

ADAM17 ProteinAngiotensin-Converting Enzyme 2Antiviral AgentsCOVID-19 Drug TreatmentSARS-CoV-2Cell LineCOVID-19HumansACE2 protein, humanADAM17 ProteinADAM17 protein, humanAngiotensin-Converting Enzyme 2Antiviral AgentsADAM17Antiviral activityArylsulfonamido-based hydroxamic acidsACE2SARS-CoV-2

Identifiers

PMID39292373
PMCPMC11743353

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.